Yuqing (Sheri) Hao is an Associate Director at HighLight Capital, Shanghai, China, where she focuses on early-stage life-science investing and portfolio support. She brings around a decade of experience spanning biotech R&D, external innovation, and venture investing. 

Prior to her current role, Yuqing served as Principal Scientist II at Boehringer Ingelheim, where she contributed to scouting and evaluating external opportunities, conducting disease-area assessments to inform longer-range strategy, and initiating academic collaborations aligned with evolving portfolio priorities.

Earlier in her career, she was a Principal Investigator at BeiOne, where she led project initiation from concept, driving the internal process to establish new programs and supporting oncology discovery and translational efforts. She completed postdoctoral training at Karolinska Institutet in Sweden, applying biochemical and proteomics approaches to investigate cancer-relevant cellular pathways.

Yuqing earned her PhD in Biology from Heidelberg University in Germany, and holds an MSc in Biochemistry and Molecular Biology and a Bachelor of Medicine from Fudan University.